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baseline cholesterol levels and relevant co-morbidity. RESULTS:
A total of 2341 patients were identiﬁed, of these 644 were initi-
ated on rosuvastatin (93% on 10 mg), 606 on atorvastatin (53%
on 10 mg, 39% on 20 mg), 613 on simvastatin (70% on 20 mg),
440 on pravastatin (79% on 40 mg) and 38 on ﬂuvastatin (79%
on 80 mg). Secondary prevention accounted for approximately
30% of patients. Average percent LDL-C reductions were 48.0
(CI95%: 46.6–49.5), 41.7 (CI95%: 39.9–43.4), 38.7 (CI95%:
37.3–40.0), 32.0 (CI95%: 30.1–33.9), and 29.7 (CI95%:
23.9–35.5) for rosuvastatin, atorvastatin, simvastatin, pravas-
tatin and ﬂuvastatin respectively. The proportion of patients
attaining cholesterol goals was 75% for rosuvastatin, 68% for
atorvastatin, 56% for simvastatin, 42% for pravastatin, and
34% for ﬂuvastatin. After adjustment for risk factors the use of
rosuvastatin was signiﬁcantly associated with both greater LDL-
C reduction (mean differences 5.4% to 18.3%, all p < 0.001),
and with increased goal attainment (odds ratios 0.60 to 0.11, all
p < 0.001) compared to users of other statins. CONCLUSION:
We found evidence that in a real life setting, both percentage
LDL-C reduction and the proportion of patients attaining 2003
European cholesterol goals is signiﬁcantly greater among users
of rosuvastatin compared to other statins. Results are consistent
with those reported in clinical trials.
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OBJECTIVE: To examine Medicare resource utilization and
costs among patients with congestive heart failure (CHF) over
the course of one year after an initial CHF hospital discharge.
METHODS: Statistical analyses were conducted on Medicare
Standard Analytic Files. A cohort of patients with an initial inpa-
tient hospitalization for CHF between January 1, 1999 and
December 31, 2000 were identiﬁed and followed for a period of
one year. Outcomes assessed included the number of readmis-
sions (CHF-related and all-cause) and emergency department
(ED) visits; the mean time to each readmission/visit; mortality
following discharge; number and timing of physician ofﬁce visits;
and total charges. Multivariate regression analyses were con-
ducted to assess the likelihood of hospital readmission, likeli-
hood of death, and total charges adjusting for patient
characteristics and compliance with routine care. RESULTS: A
cohort of 690,800 patients (weighted) was identiﬁed. Within one
year of their initial hospitalization, approximately 20 percent of
patients (136,460; 19.75%) were readmitted for CHF and over
one-half (350,660; 50.76%) were readmitted for all causes. The
time-to-event analysis revealed that increasing the time to ﬁrst
readmission decreases the overall number of readmissions and
associated costs. Over 50% of patients visited the ED within 3
months of hospital discharge. The one-year mortality rate was
31.4%. The patient population that was readmitted within 30
days of initial hospital discharge accumulated the highest total
charges over the course of the year (mean = $66,639). In the mul-
tivariate model, the main cost drivers were the number of hos-
pital readmissions and death anytime within the year (potentially
due to high end-of-life costs). CONCLUSIONS: The large pro-
portion of hospital readmissions and ED visits occurring shortly
after discharge suggests that many patients are not sufﬁciently
managed once outside the hospital. Increased compliance with
physician visits could help decrease the overall number of both
CHF-related and all-cause readmissions.
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All cause mortality in the placebo group of ASCOT-LLA (Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid-Lowering arm) was
1.28%. ASCOT-LLA included hypertensive patients (HP) in
primary prevention, with TC ≥ 6.5 mmol/L, not treated with
statins and with at least 3 cardiovascular risk factors (CVRF). A
lower CV morbimortality with atorvastatin ten mg vs placebo
was demonstrated. OBJECTIVES: Evaluate the real world mor-
tality of HP as deﬁned in ASCOT-LLA in a Mediterranean pop-
ulation of HP not treated with statins. METHODS: Patients
from seven primary care centres with a diagnosis of HT (CIAP
= K86-K87) were included in a multicentric registry of one year
follow-up (2004–2005) (n = 6309 patients). Main analysed vari-
ables were: basal age-sex, diabetes mellitus, stroke, smoking,
TC/HDL-ratio and all cause mortality (2004). RESULTS: Of the
6309 patients, 2528 (40%) had a history of CHD and/or heart
failure (HF) and/or TC > 6.5 mmol/L and/or statin treatment and
were excluded from the analysis. In the remaining 3781, CVFR
≥ 3 was conﬁrmed in 831. The annual mortality of these patients
was 2.89%, greater than ASCOT-LLA placebo group. In the
group of 3781 patients with no history of cardiac disease nor
TC > 6.5 mmol/L and without statin treatment, those with CVRF
≥ 3 had a higher mortality (2.89%) vs CVRF < 3 (1.86%)
(Fisher: p = 0.0497; χ2 : p = 0.0795). A signiﬁcant relationship
was demonstrated among CVRF number and mortality: 0
CVRF-0% mortality; 1 CVRF:1.4% mortality; 2 CVRF:2.7%
mortality; 3 CVRF:2.0% mortality; 4 CVRF:4.8% mortality; ≥5
CVRF:5.9% mortality (Mantel-Haenzel test: p = 0.003). CON-
CLUSIONS: Our data suggest that real world mortality of
ASCOT-like hypertensives in a Mediterranean population is
greater than the mortality found in the ASCOT (2.89% vs.
1.29%). A signiﬁcant relationship was demonstrated among
CVRF and mortality. Our data also suggest that the presence of
CVRF ≥ 3 indicates a high mortality risk.
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OBJECTIVE: Rimonabant, the ﬁrst selective CB-1 receptor
blocker, has proven effective in improving cardiometabolic risk
factors and reducing weight in overweight and obese individu-
als. This study evaluated its cost-effectiveness in patients with a
BMI > 27 kg/m2 in the UK. METHODS: A discrete event simu-
lation was created to take into account multiple time-dependent
risk factors—it predicts changes in anthropomorphic and phys-
iologic parameters based on analysis of pooled RIO trials data,
while simultaneously predicting onset of diabetes, cardiovascu-
